U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07949474) titled 'Semaglutide in Alcohol Use Disorder' on Nov. 13.

Brief Summary: This is a 45-week, randomized, double-blind, placebo-controlled clinical trial designed to compare the effectiveness of semaglutide versus placebo on alcohol-related outcomes among 128 adults with alcohol use disorder (AUD) and obesity.

Study Start Date: May 01, 2027

Study Type: INTERVENTIONAL

Condition: Alcohol Use Disorder (AUD) Obesity

Intervention: DRUG: Wegovy

Participants in this arm will receive 42 weeks of treatment with semaglutide

OTHER: Placebo

Participants in this arm will receive 42 weeks of placebo

Recruitment Status: NOT_YET_RECRUITING

Sponsor:...